ProMetic Life Sciences Inc. (TSE:PLI) shares traded up 5.3% on Friday . The stock traded as high as C$1.65 and last traded at C$1.59. 1,226,966 shares changed hands during trading, a decline of 29% from the average session volume of 1,729,067 shares. The stock had previously closed at C$1.51.
Several research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of ProMetic Life Sciences in a research note on Monday, November 20th. National Bank Financial dropped their price target on shares of ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 15th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of C$3.50.
The stock has a market cap of $1,110.00, a P/E ratio of -9.18 and a beta of 2.39.
WARNING: This story was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.thelincolnianonline.com/2018/01/14/prometic-life-sciences-pli-trading-5-3-higher.html.
ProMetic Life Sciences Company Profile
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.